An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Aspira Women’s Health Inc. will report its financial results for the three months ended September 30, 2023 on November 13, 2023. The company will host a conference call with investors at 4:30 p.m. Eastern Time to discuss financial results and provide a corporate update. Participants can join the call using the provided toll-free and international numbers or access the event instantly through the Call me™ link. A replay of the webcast will be available on the company's Investor Relations website.
Positive
None.
Negative
None.
AUSTIN, Texas, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”), a bio-analytical company focused on the development and commercialization of women’s health diagnostic tools for gynecologic diseases, today announced that the company will report its financial results for the three months ended September 30, 2023 on Monday, November 13, 2023. Management will also host a conference call with investors to discuss financial results and provide a corporate update at 4:30 p.m. Eastern Time. Details for the call are as follows:
Participants can use Guest dial-in numbers above and be answered by an operator OR participants can click the Call me™ link for instant telephone access to the event. The Call me™ link will be made active 15 minutes prior to the scheduled start time.
A replay of the webcast will also be available on the Events & Presentation page of the Aspira Women’s Health Investor Relations website.
About Aspira Women’s Health Inc. Aspira Women’s Health Inc. is transforming women’s gynecological health with the discovery, development, and commercialization of innovative testing options for women of all races and ethnicities, starting with ovarian cancer.
Our ovarian cancer risk assessment portfolio is marketed to healthcare providers as OvaSuiteSM, which includes OvaWatchSM, a non-invasive, blood-based test intended for use in the initial clinical assessment of ovarian cancer risk in women with benign or indeterminate adnexal masses for which surgical intervention may be either premature or unnecessary. With a negative predictive value (NPV) of 99%, OvaWatch allows physicians to confidently rule out ovarian cancer malignancy and choose the appropriate clinical management for the right patient at the right time. Ova1Plus® combines our FDA-cleared products, Ova1® and Overa®, to detect risk of ovarian malignancy in women with adnexal masses planned for surgery.
EndoCheckSM, Aspira’s first-of-its-kind non-invasive diagnostic test for endometriosis, is currently in development. Visit our website for more information at www.aspirawh.com.
When will Aspira Women’s Health Inc. report its financial results?
Aspira Women’s Health Inc. will report its financial results for the three months ended September 30, 2023 on November 13, 2023.
What is the purpose of the conference call hosted by Aspira Women’s Health Inc.?
The conference call hosted by Aspira Women’s Health Inc. is for discussing financial results and providing a corporate update.
How can participants join the conference call?
Participants can join the conference call using the provided toll-free and international numbers or access the event instantly through the Call me™ link.
Where can I find a replay of the webcast?
A replay of the webcast will be available on the Events & Presentation page of the Aspira Women’s Health Investor Relations website.
vermillion, inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic and bio-analytical solutions that help physicians diagnose, treat and improve gynecologic health outcomes for women. vermillion, along with its prestigious scientific collaborators, discovers, develops, and delivers innovative diagnostic and technology tools that help women with serious diseases. the company’s initial in vitro diagnostic test, ova1®, was the first fda-cleared, protein-based in vitro diagnostic multivariate index assay, and represented a new class of software-based liquid biopsy in vitro diagnostics. in march 2016 vermillion received fda clearance for overa™, a second generation ova1 test with significantly improved specificity and ease of use.